Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study

Hdl Handle:
http://hdl.handle.net/10144/619082
Title:
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study
Authors:
Ferlazzo, G; Mohr, E; Laxmeshwar, C; Hewison, C; Hughes, J; Jonckheere, S; Khachatryan, N; De Avezedo, V; Egazaryan, L; Shroufi, A; Kalon, S; Cox, H; Furin, J; Isaakidis, P
Journal:
The Lancet. Infectious Diseases
Abstract:
Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients have been unable to access the two drugs in combination. Médecins Sans Frontières has supported the use of combination bedaquiline and delamanid for people with few treatment options since 2016. We describe early safety and efficacy of regimens containing the bedaquiline and delamanid combination in patients with drug-resistant tuberculosis in Yerevan, Armenia; Mumbai, India; and Khayelitsha, South Africa.
Publisher:
Elsevier
Issue Date:
13-Feb-2018
URI:
http://hdl.handle.net/10144/619082
DOI:
10.1016/S1473-3099(18)30100-2
PubMed ID:
29452942
Submitted date:
2018-02-22
Language:
en
ISSN:
1474-4457
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorFerlazzo, Gen
dc.contributor.authorMohr, Een
dc.contributor.authorLaxmeshwar, Cen
dc.contributor.authorHewison, Cen
dc.contributor.authorHughes, Jen
dc.contributor.authorJonckheere, Sen
dc.contributor.authorKhachatryan, Nen
dc.contributor.authorDe Avezedo, Ven
dc.contributor.authorEgazaryan, Len
dc.contributor.authorShroufi, Aen
dc.contributor.authorKalon, Sen
dc.contributor.authorCox, Hen
dc.contributor.authorFurin, Jen
dc.contributor.authorIsaakidis, Pen
dc.date.accessioned2018-03-09T15:47:19Z-
dc.date.available2018-03-09T15:47:19Z-
dc.date.issued2018-02-13-
dc.date.submitted2018-02-22-
dc.identifier.citationEarly safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. 2018 Lancet Infect Disen
dc.identifier.issn1474-4457-
dc.identifier.pmid29452942-
dc.identifier.doi10.1016/S1473-3099(18)30100-2-
dc.identifier.urihttp://hdl.handle.net/10144/619082-
dc.description.abstractBedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients have been unable to access the two drugs in combination. Médecins Sans Frontières has supported the use of combination bedaquiline and delamanid for people with few treatment options since 2016. We describe early safety and efficacy of regimens containing the bedaquiline and delamanid combination in patients with drug-resistant tuberculosis in Yerevan, Armenia; Mumbai, India; and Khayelitsha, South Africa.en
dc.language.isoenen
dc.publisherElsevieren
dc.rightsArchived with thanks to The Lancet. Infectious Diseasesen
dc.titleEarly safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort studyen
dc.identifier.journalThe Lancet. Infectious Diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.